In routine setting, interdisciplinary teams satisfactorily manage extravasations
the ONA take:
In a routine setting, the standardized management of cytotoxic extravasations of antitumoral compounds by an interdisciplinary task force resulted in a satisfactory outcome, a study published in the journal Supportive Care in Cancer has shown.
For the study, researchers sought to assess extravasations of antitumoral compounds and the efficacy of its structured interdisciplinary managements in a routine setting. Researchers longitudinally observed 169 patients who were managed for cytotoxic extravasation according to a prospective approach. Patients underwent surgery if conservative measures failed.
Results showed that conservative management was successful in 91.7% of patients. Researchers found that extravasations of anthracyclines (i.e., doxorubicin), platinum compounds (i.e., cisplatin), vinca alkaloids (i.e., vincristine), and taxanes (i.e., paclitaxel) were associated with erythema, edema, and pain.
The median duration until full resolution of symptoms was 55 days for anthracyclines, 27 days for taxanes and vinca alkaloids, and 14 days for platinum compounds, with statistical significance between the vesicants.
The findings suggest that "the proposed approach is therefore considered as suitable to manage extravasations in cancer chemotherapy in a large number of subjects and to ensure patient adherence to cytotoxic treatment."
In a routine setting, the standardized management of cytotoxic extravasations resulted in a satisfactory outcome.
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Rubraca Granted Accelerated FDA Approval for Advanced BRCA-positive Ovarian Cancer
- New Criteria for Appropriate Use of Bone Scintigraphy to Diagnose and Manage Prostate and Breast Cancer
- Primary Care Physicians Surveyed on Breast Cancer Screening Practices
- Low Acculturated Latina Women Reported Breast Cancer Treatment Experience Differently Than Other Groups
- Cost and Complication Rates Differ Among Early Breast Cancer Treatment Options
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|